Search

Your search keyword '"Bermejo F"' showing total 11 results
Start Over Author "Bermejo F" Journal alimentary pharmacology & therapeutics
11 results on '"Bermejo F"'

1. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

Author

Gisbert, J. P., Romano, M., Gravina, A. G., Solís-Muñoz, P., Bermejo, F., Molina-Infante, J., Castro-Fernández, M., Ortuño, J., Lucendo, A. J., Herranz, M., Modolell, I., del Castillo, F., Gómez, J., Barrio, J., Velayos, B., Gómez, B., Domínguez, J. L., Miranda, A., Martorano, M., Algaba, A., Pabón, M., Angueira, T., Fernández-Salazar, L., Federico, A., Marín, A. C., and McNicholl, A. G.

Published
2015
Full Text
View/download PDF

2. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study

Author

Molina-Infante, J., Lucendo, A. J., Angueira, T., Rodriguez-Tellez, M., Perez-Aisa, A., Balboa, A., Barrio, J., Martin-Noguerol, E., Gomez-Rodriguez, B. J., Botargues-Bote, J. M., Gomez-Camarero, J., Huerta, A., Modolell, I., Ariño, I., Herranz-Bachiller, M. T., Bermejo, F., McNicholl, A. G., OʼMorain, C., Gisbert, J. P., Lima, A., Tejero-Bustos, M. A., Sans, M., Mearin, F., Perez-Lasala, J., Mañas-Gallardo, N., Millastre, J., Gracia, M., Rodriguez-Sanchez, J., Rancel-Medina, F. J., Lanas, A., and Prados, S.

Published
2015
Full Text
View/download PDF

3. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Author

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, and GETECCU study group

Subjects
Adult, Male, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Communicable Diseases, Inflammatory bowel disease, Vedolizumab, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Gastrointestinal Agents, Interquartile range, Internal medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, Registries, Adverse effect, Prospective cohort study, Hepatology, business.industry, Proportional hazards model, Remission Induction, Gastroenterology, Middle Aged, Inflammatory Bowel Diseases, medicine.disease, Ulcerative colitis, Discontinuation, Treatment Outcome, Spain, 030220 oncology & carcinogenesis, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, business, Follow-Up Studies, medicine.drug
Abstract

Background: Effectiveness of vedolizumab in real world clinical practice is unknown. Aim: To evaluate the short and long-term effectiveness of vedolizumab in patients with inflammatory bowel disease (IBD). Methods: Patients who received at least 1 induction dose of vedolizumab were included. Effectiveness was defined based on Harvey-Bradshaw index (HBI) in Crohn's disease (CD) and Partial Mayo Score (PMS) in ulcerative colitis (UC). Short-term response was assessed at week 14. Variables associated with short-term remission were identified by logistic regression analysis. The Kaplan-Meier method was used to evaluate the long-term durability of vedolizumab treatment. Cox model was used to identify factors associated with discontinuation of treatment and loss of response. Results: 521 patients were included (median follow-up 10 months [interquartile range 5-18 months]). At week 14, 46.8% had remission and 15.7% clinical response. CD (vs UC), previous surgery, higher CRP concentration and disease severity at baseline were significantly associated with impaired response. The rate of vedolizumab discontinuation was 37% per patient-year of follow-up (27.6% in UC and 45.3% in CD, P < 0.01). CD (vs UC), anaemia at baseline, steroids during induction and CRP concentration were associated with lower durability of treatment. Seven per cent of patients developed adverse events, infections being the most frequent. Conclusions: Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short- and long-term response. Vedolizumab seems to be safe in clinical practice.

Published
2018

4. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients

Author

González-Lama, Y., Bermejo, F., López-Sanromán, A., García-Sánchez, V., Esteve, M., Cabriada, J. L., McNicholl, A. G., Pajares, R., Casellas, F., Merino, O., Carpio, D., Vera, M. I., Muñoz, C., Benito, L. M., Bujanda, L., García-Fernández, F. J., Ricart, E., Ginard, D., Velasco, M., Carneros, J. A., Manceñido, N., Calvo, M., Algaba, A., Froilan, C., Cara, C., Maté, J., Abreu, L., and Gisbert, J. P.

Published
2011
Full Text
View/download PDF

10. Helicobacter pylorisecond-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

Author

Gisbert, J. P., primary, Romano, M., additional, Gravina, A. G., additional, Solís-Muñoz, P., additional, Bermejo, F., additional, Molina-Infante, J., additional, Castro-Fernández, M., additional, Ortuño, J., additional, Lucendo, A. J., additional, Herranz, M., additional, Modolell, I., additional, del Castillo, F., additional, Gómez, J., additional, Barrio, J., additional, Velayos, B., additional, Gómez, B., additional, Domínguez, J. L., additional, Miranda, A., additional, Martorano, M., additional, Algaba, A., additional, Pabón, M., additional, Angueira, T., additional, Fernández-Salazar, L., additional, Federico, A., additional, Marín, A. C., additional, and McNicholl, A. G., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results